BACKGROUND: In advanced renal cell carcinoma (RCC), sunitinib and sorafenib tyrosine kinase inhibitors (TKI) are associated with several clinical side effects, with no definitive established data concerning their clinical impact.
METHODS: From June 2006 to June 2008, main clinical TKI-induced toxicities, including digestive, cardiac, dermatologic and asthenia were retrospectively collected using the NCI-CTC version 3.0 in patients treated with TKI for an RCC.
RESULTS: The median overall survival was significantly improved in patients with grade 3-4 clinical toxicities (36 vs 12 months, P=0.009). In multivariate analysis, the Memorial Sloan-Kettering Cancer Center risk groups (good vs intermediate or poor) and clinical toxicities (grade 3-4 vs 1-2) were identified as independent prognostic factors of better survival (P=0.002 and P=0.02, respectively). The Charlson comorbidity index score (>7 vs < 7) was identified as independent predictive factor of severe clinical TKI-induced toxicities (P=0.02).
CONCLUSION: In this unselected patients of RCC, clinical TKI-related severe toxicities were more frequent in patients with comorbidities and were associated with better survival.
Written by:
Di Fiore F, Rigal O, Ménager C, Michel P, Pfister C. Are you the author?
Digestive Oncology Unit, Department of Gastroenterology, Rouen University Hospital, 1 rue de Germont, Rouen Cedex, France.
Reference: Br J Cancer. 2011 Dec 6;105(12):1811-3.
doi: 10.1038/bjc.2011.507
PubMed Abstract
PMID: 22095228
UroToday.com Renal Cancer Section
